US Patent Issued to FRED HUTCHINSON CANCER CENTER on Oct. 21 for "High avidity WT1 T cell receptors and uses thereof" (Washington Inventors)

ALEXANDRIA, Va., Oct. 28 -- United States Patent no. 12,448,430, issued on Oct. 21, was assigned to FRED HUTCHINSON CANCER CENTER (Seattle).

"High avidity WT1 T cell receptors and uses thereof" was invented by Thomas M. Schmitt (Seattle), Aude G. Chapuis (Seattle) and Philip D. Greenberg (Mercer Island, Wash.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides T cell receptors (TCRs) and related binding proteins with high functional avidity against tumor associated antigen p37 from Wilms tumor protein 1 (WT1), T cells expressing such high affinity WT1 specific TCRs, nucleic acids encoding the same, and compositions for use in treating diseases or disorders in which cells overexpres...